<< Back to News

New FDA Approval for Merck'ssingle-dose EMEND® (fosaprepitant dimeglumine)

On Feb. 4, 2016 Merck announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for single-dose EMEND® (fosaprepitant dimeglumine) for injection, Merck’s substance P/neurokinin-1 (NK1) receptor antagonist, in combination with other antiemetic medicines, for the prevention of delayed nausea and vomiting in adults receiving initial and repeat courses of moderately emetogenic chemotherapy (MEC). 

Click Here to read the Press Release from Merck.

Click Here to read Merck's Announcement Letter.